Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat Replacement in PAH (REPLACE)
NCT02891850Phase 4Completed
- Sponsor
- Bayer
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 4 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Jan 2017; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02891850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891850.